User menu

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.

Bibliographic reference Seremet, Teofila ; Koch, Alexander ; Jansen, Yanina ; Schreuer, Max ; Wilgenhof, Sofie ; et. al. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.. In: Journal of Translational Medicine, Vol. 14, no.1, p. 232 (2016)
Permanent URL http://hdl.handle.net/2078.1/182273
  1. Adams S, et al. Spontaneous immune responses to melanoma-associated antigens in melanoma, vitiligo and healthy controls. ASCO Meet Abstr. 2005;23:9682.
  2. Bramhall R.J., Mahady K., Peach A.H.S., Spontaneous regression of metastatic melanoma – Clinical evidence of the abscopal effect, 10.1016/j.ejso.2013.09.026
  3. Chambers Cynthia A., Kuhns Michael S., Egen Jackson G., Allison James P., CTLA-4-MEDIATED INHIBITION IN REGULATION OF T CELL RESPONSES: Mechanisms and Manipulation in Tumor Immunotherapy, 10.1146/annurev.immunol.19.1.565
  4. Snyder Alexandra, Makarov Vladimir, Merghoub Taha, Yuan Jianda, Zaretsky Jesse M., Desrichard Alexis, Walsh Logan A., Postow Michael A., Wong Phillip, Ho Teresa S., Hollmann Travis J., Bruggeman Cameron, Kannan Kasthuri, Li Yanyun, Elipenahli Ceyhan, Liu Cailian, Harbison Christopher T., Wang Lisu, Ribas Antoni, Wolchok Jedd D., Chan Timothy A., Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, 10.1056/nejmoa1406498
  5. Simpson Tyler R., Li Fubin, Montalvo-Ortiz Welby, Sepulveda Manuel A., Bergerhoff Katharina, Arce Frederick, Roddie Claire, Henry Jake Y., Yagita Hideo, Wolchok Jedd D., Peggs Karl S., Ravetch Jeffrey V., Allison James P., Quezada Sergio A., Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma, 10.1084/jem.20130579
  6. Hodi F. Stephen, O'Day Steven J., McDermott David F., Weber Robert W., Sosman Jeffrey A., Haanen John B., Gonzalez Rene, Robert Caroline, Schadendorf Dirk, Hassel Jessica C., Akerley Wallace, van den Eertwegh Alfons J.M., Lutzky Jose, Lorigan Paul, Vaubel Julia M., Linette Gerald P., Hogg David, Ottensmeier Christian H., Lebbé Celeste, Peschel Christian, Quirt Ian, Clark Joseph I., Wolchok Jedd D., Weber Jeffrey S., Tian Jason, Yellin Michael J., Nichol Geoffrey M., Hoos Axel, Urba Walter J., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, 10.1056/nejmoa1003466
  7. Maio Michele, Grob Jean-Jacques, Aamdal Steinar, Bondarenko Igor, Robert Caroline, Thomas Luc, Garbe Claus, Chiarion-Sileni Vanna, Testori Alessandro, Chen Tai-Tsang, Tschaika Marina, Wolchok Jedd D., Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial, 10.1200/jco.2014.56.6018
  8. Schadendorf Dirk, Hodi F. Stephen, Robert Caroline, Weber Jeffrey S., Margolin Kim, Hamid Omid, Patt Debra, Chen Tai-Tsang, Berman David M., Wolchok Jedd D., Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, 10.1200/jco.2014.56.2736
  9. Robert Caroline, Thomas Luc, Bondarenko Igor, O'Day Steven, Weber Jeffrey, Garbe Claus, Lebbe Celeste, Baurain Jean-François, Testori Alessandro, Grob Jean-Jacques, Davidson Neville, Richards Jon, Maio Michele, Hauschild Axel, Miller Wilson H., Gascon Pere, Lotem Michal, Harmankaya Kaan, Ibrahim Ramy, Francis Stephen, Chen Tai-Tsang, Humphrey Rachel, Hoos Axel, Wolchok Jedd D., Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, 10.1056/nejmoa1104621
  10. Di Giacomo Anna Maria, Ascierto Paolo A, Pilla Lorenzo, Santinami Mario, Ferrucci Pier Francesco, Giannarelli Diana, Marasco Antonella, Rivoltini Licia, Simeone Ester, Nicoletti Stefania VL, Fonsatti Ester, Annesi Diego, Queirolo Paola, Testori Alessandro, Ridolfi Ruggero, Parmiani Giorgio, Maio Michele, Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial, 10.1016/s1470-2045(12)70324-8
  11. Postow Michael A., Chesney Jason, Pavlick Anna C., Robert Caroline, Grossmann Kenneth, McDermott David, Linette Gerald P., Meyer Nicolas, Giguere Jeffrey K., Agarwala Sanjiv S., Shaheen Montaser, Ernstoff Marc S., Minor David, Salama April K., Taylor Matthew, Ott Patrick A., Rollin Linda M., Horak Christine, Gagnier Paul, Wolchok Jedd D., Hodi F. Stephen, Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, 10.1056/nejmoa1414428
  12. Van Lint Sandra, Wilgenhof Sofie, Heirman Carlo, Corthals Jurgen, Breckpot Karine, Bonehill Aude, Neyns Bart, Thielemans Kris, Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula, 10.1007/s00262-014-1558-3
  13. Wilgenhof S., Van Nuffel A. M. T., Benteyn D., Corthals J., Aerts C., Heirman C., Van Riet I., Bonehill A., Thielemans K., Neyns B., A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients, 10.1093/annonc/mdt245
  14. Wilgenhof Sofie, Corthals Jurgen, Heirman Carlo, van Baren Nicolas, Lucas Sophie, Kvistborg Pia, Thielemans Kris, Neyns Bart, Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma, 10.1200/jco.2015.63.4121
  15. Seib Carolyn D., Rocha Flavio G., Hwang Dick G., Shoji Brent T., Gastrosplenic Fistula From Hodgkin's Lymphoma, 10.1200/jco.2008.21.7695
  16. Ulloa-Montoya Fernando, Louahed Jamila, Dizier Benjamin, Gruselle Olivier, Spiessens Bart, Lehmann Frédéric F., Suciu Stefan, Kruit Wim H.J., Eggermont Alexander M.M., Vansteenkiste Johan, Brichard Vincent G., Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy, 10.1200/jco.2012.44.3762
  17. Spranger Stefani, Bao Riyue, Gajewski Thomas F., Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity, 10.1038/nature14404
  18. Zelenay Santiago, van der Veen Annemarthe G., Böttcher Jan P., Snelgrove Kathryn J., Rogers Neil, Acton Sophie E., Chakravarty Probir, Girotti Maria Romina, Marais Richard, Quezada Sergio A., Sahai Erik, Reis e Sousa Caetano, Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity, 10.1016/j.cell.2015.08.015
  19. Wilgenhof Sofie, Four Stephanie Du, Vandenbroucke Frederik, Everaert Hendrik, Salmon Isabelle, Liénard Danielle, Marmol Véronique Del, Neyns Bart, Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma : , 10.1097/cji.0b013e31828eed39
  20. Marshall Christy L., Liebig Catherine, Ayala Gustavo, Wilks Jonathan, Verstovsek Gordana, Liu Hao, Agarwal Neeti, Berger David H., Albo Daniel, Reply to E.M. Poeschl et al, 10.1200/jco.2009.27.4100
  21. Hamid Omid, Schmidt Henrik, Nissan Aviram, Ridolfi Laura, Aamdal Steinar, Hansson Johan, Guida Michele, Hyams David M, Gómez Henry, Bastholt Lars, Chasalow Scott D, Berman David, A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, 10.1186/1479-5876-9-204
  22. Wang Wenshi, Yu Daohai, Sarnaik Amod A, Yu Bin, Hall Maclean, Morelli Dawn, Zhang Yonghong, Zhao Xiuhua, Weber Jeffrey S, Biomarkers on melanoma patient T Cells associated with ipilimumab treatment, 10.1186/1479-5876-10-146
  23. Ribas A et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol. 2015;33(15). (suppl, abstr 3001).
  24. Ayers Mark, Lunceford Jared, Nebozhyn Michael, Murphy Erin, Loboda Andrey, Albright Andrew, Cheng Jonathan, Kang S Peter, Ebbinghaus Scot, Yearley Jennifer, Shankaran Veena, Seiwert Tanguy, Ribas Antoni, McClanahan Terri, Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors, 10.1186/2051-1426-3-s2-p80
  25. De Meyer Tim, Mampaey Evi, Vlemmix Michaël, Denil Simon, Trooskens Geert, Renard Jean-Pierre, De Keulenaer Sarah, Dehan Pierre, Menschaert Gerben, Van Criekinge Wim, Quality Evaluation of Methyl Binding Domain Based Kits for Enrichment DNA-Methylation Sequencing, 10.1371/journal.pone.0059068
  26. Langmead Ben, Trapnell Cole, Pop Mihai, Salzberg Steven L, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, 10.1186/gb-2009-10-3-r25
  27. Kim Daehwan, Pertea Geo, Trapnell Cole, Pimentel Harold, Kelley Ryan, Salzberg Steven L, TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions, 10.1186/gb-2013-14-4-r36
  28. Anders S., Pyl P. T., Huber W., HTSeq--a Python framework to work with high-throughput sequencing data, 10.1093/bioinformatics/btu638
  29. Robinson M. D., McCarthy D. J., Smyth G. K., edgeR: a Bioconductor package for differential expression analysis of digital gene expression data, 10.1093/bioinformatics/btp616
  30. Eden Eran, Navon Roy, Steinfeld Israel, Lipson Doron, Yakhini Zohar, GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists, 10.1186/1471-2105-10-48
  31. Germain Claire, Gnjatic Sacha, Dieu-Nosjean Marie-Caroline, Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity, 10.3389/fimmu.2015.00067
  32. Nielsen J. S., Sahota R. A., Milne K., Kost S. E., Nesslinger N. J., Watson P. H., Nelson B. H., CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer, 10.1158/1078-0432.ccr-12-0234
  33. Pretscher Dominik, Distel Luitpold V, Grabenbauer Gerhard G, Wittlinger Michael, Buettner Maike, Niedobitek Gerald, Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma, 10.1186/1471-2407-9-292
  34. Shi J.-Y., Gao Q., Wang Z.-C., Zhou J., Wang X.-Y., Min Z.-H., Shi Y.-H., Shi G.-M., Ding Z.-B., Ke A.-W., Dai Z., Qiu S.-J., Song K., Fan J., Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma, 10.1158/1078-0432.ccr-12-3497
  35. Meshcheryakova Anastasia, Tamandl Dietmar, Bajna Erika, Stift Judith, Mittlboeck Martina, Svoboda Martin, Heiden Denise, Stremitzer Stefan, Jensen-Jarolim Erika, Grünberger Thomas, Bergmann Michael, Mechtcheriakova Diana, B Cells and Ectopic Follicular Structures: Novel Players in Anti-Tumor Programming with Prognostic Power for Patients with Metastatic Colorectal Cancer, 10.1371/journal.pone.0099008
  36. Germain Claire, Gnjatic Sacha, Tamzalit Fella, Knockaert Samantha, Remark Romain, Goc Jérémy, Lepelley Alice, Becht Etienne, Katsahian Sandrine, Bizouard Geoffray, Validire Pierre, Damotte Diane, Alifano Marco, Magdeleinat Pierre, Cremer Isabelle, Teillaud Jean-Luc, Fridman Wolf-Herman, Sautès-Fridman Catherine, Dieu-Nosjean Marie-Caroline, Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer, 10.1164/rccm.201309-1611oc
  37. Wirsing Anna M, Rikardsen Oddveig G, Steigen Sonja E, Uhlin-Hansen Lars, Hadler-Olsen Elin, Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma, 10.1186/1472-6890-14-38
  38. Yuan J., Adamow M., Ginsberg B. A., Rasalan T. S., Ritter E., Gallardo H. F., Xu Y., Pogoriler E., Terzulli S. L., Kuk D., Panageas K. S., Ritter G., Sznol M., Halaban R., Jungbluth A. A., Allison J. P., Old L. J., Wolchok J. D., Gnjatic S., Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab, 10.1073/pnas.1110814108
  39. Cipponi A., Mercier M., Seremet T., Baurain J.-F., Theate I., van den Oord J., Stas M., Boon T., Coulie P. G., van Baren N., Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases, 10.1158/0008-5472.can-12-1377
  40. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC, Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer, 10.1038/bjc.1996.28
  41. Lou Y, et al. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res. 2005;65:7926–33.
  42. Lou Y., Basha G., Seipp R. P., Cai B., Chen S. S., Moise A. R., Jeffries A. P., Gopaul R. S., Vitalis T. Z., Jefferies W. A., Combining the Antigen Processing Components TAP and Tapasin Elicits Enhanced Tumor-Free Survival, 10.1158/1078-0432.ccr-07-1066
  43. Shreders A., Joseph R., Peng C., Ye F., Zhao S., Puzanov I., Sosman J. A., Johnson D. B., Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab, 10.1158/2326-6066.cir-15-0281
  44. Hamid Omid, Robert Caroline, Daud Adil, Hodi F. Stephen, Hwu Wen-Jen, Kefford Richard, Wolchok Jedd D., Hersey Peter, Joseph Richard W., Weber Jeffrey S., Dronca Roxana, Gangadhar Tara C., Patnaik Amita, Zarour Hassane, Joshua Anthony M., Gergich Kevin, Elassaiss-Schaap Jeroen, Algazi Alain, Mateus Christine, Boasberg Peter, Tumeh Paul C., Chmielowski Bartosz, Ebbinghaus Scot W., Li Xiaoyun Nicole, Kang S. Peter, Ribas Antoni, Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma, 10.1056/nejmoa1305133
  45. Weber Jeffrey S., Kudchadkar Ragini Reiney, Yu Bin, Gallenstein Donna, Horak Christine E., Inzunza H. David, Zhao Xiuhua, Martinez Alberto J., Wang Wenshi, Gibney Geoffrey, Kroeger Jodi, Eysmans Cabell, Sarnaik Amod A., Chen Y. Ann, Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma, 10.1200/jco.2013.51.4802
  46. Huang Xiao, Saint-Jeannet Jean-Pierre, Induction of the neural crest and the opportunities of life on the edge, 10.1016/j.ydbio.2004.07.033
  47. Zabierowski Susan E., Baubet Valerie, Himes Benjamin, Li Ling, Fukunaga-kalabis Mizuho, Patel Sonal, McDaid Ronan, Guerra Matt, Gimotty Phyllis, Dahamne Nadia, Herlyn Meenhard, Direct Reprogramming of Melanocytes to Neural Crest Stem-Like Cells by One Defined Factor, 10.1002/stem.740
  48. Hölzel Michael, Bovier Anton, Tüting Thomas, Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?, 10.1038/nrc3498
  49. Hugo Willy, Shi Hubing, Sun Lu, Piva Marco, Song Chunying, Kong Xiangju, Moriceau Gatien, Hong Aayoung, Dahlman Kimberly B., Johnson Douglas B., Sosman Jeffrey A., Ribas Antoni, Lo Roger S., Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance, 10.1016/j.cell.2015.07.061
  50. Landsberg Jennifer, Kohlmeyer Judith, Renn Marcel, Bald Tobias, Rogava Meri, Cron Mira, Fatho Martina, Lennerz Volker, Wölfel Thomas, Hölzel Michael, Tüting Thomas, Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation, 10.1038/nature11538
  51. Jones Peter A., Functions of DNA methylation: islands, start sites, gene bodies and beyond, 10.1038/nrg3230